speb/financial-data huggingface dataset:
Financial ratios for IEP — quarterly report dated 2025-09-30
Total revenue: 2484000000
Gross profit: 799000000
Operating income: 431000000
Net income: 411000000
Capital expenditures: 82000000
Operating cash flow: 15000000
Depreciation & amortization: 158000000
Net tangible assets: 1292000000
Owner earnings: 487000000
Return on net tangible assets (%): 37.693498452012385
Capex to operating income (%): 19.02552204176334
Buffett classification: The Great
Stock price: 6.99
P/E ratio: 2.857441219872263
Shares outstanding: 672050553
Book value: 3419000000
P/B ratio: 1.3739787556215268
Market cap (USD): 4697633365.47
Debt to equity: 1.9561275226674466
Current ratio: 4.607696151924038
Quick ratio: 4.16191904047976
Effective tax rate (%): 23.605947955390334
Interest coverage ratio: 3.5327868852459017
COGS to revenue (%): 67.8341384863124
SG&A to revenue (%): 8.776167471819646
Free cash flow (dilution-adjusted): -67000000
Buyback yield (%): 0
Inventory turnover: 1.8890134529147982
Receivables turnover: 1.0962047661076788
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.3606237816764133
FCF margin (%): -2.6972624798711755
Revenue growth (%): 7.300215982721382
Rule of 40 score: 4.602953502850207
Financial ratios for IEP — annual report dated 2025-12-31
Total revenue: 9295000000
Gross profit: 1317000000
Operating income: -119000000
Net income: -293000000
Capital expenditures: 341000000
Operating cash flow: -313000000
Depreciation & amortization: 603000000
Net tangible assets: 1303000000
Owner earnings: -31000000
Return on net tangible assets (%): -2.379125095932464
Buffett classification: The Gruesome
Stock price: 6.65
Shares outstanding: 672050553
Book value: 3426000000
P/B ratio: 1.3044764090630474
Market cap (USD): 4469136177.45
Debt to equity: 1.9311150029188557
Current ratio: 4.568050446663164
Quick ratio: 4.124014713610089
Interest coverage ratio: -0.2361111111111111
COGS to revenue (%): 85.83109198493814
SG&A to revenue (%): 9.004841312533621
Free cash flow (dilution-adjusted): -654000000
Buyback yield (%): 0
Inventory turnover: 9.441420118343196
Receivables turnover: 4.267676767676767
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.9665367121507472
FCF margin (%): -7.036040882194729
Revenue growth (%): -6.111111111111111
Rule of 40 score: -13.14715199330584
Financial ratios for IEP — quarterly report dated 2025-12-31
Total revenue: 2326000000
Gross profit: 167000000
Operating income: -188000000
Net income: 44000000
Capital expenditures: 75000000
Operating cash flow: -421000000
Depreciation & amortization: 195000000
Net tangible assets: 1303000000
Owner earnings: 164000000
Return on net tangible assets (%): 12.586339217191098
Buffett classification: The Gruesome
Stock price: 6.65
P/E ratio: 25.392819190056816
Shares outstanding: 672050553
Book value: 3426000000
P/B ratio: 1.3044764090630474
Market cap (USD): 4469136177.45
Debt to equity: 1.9311150029188557
Current ratio: 4.568050446663164
Quick ratio: 4.124014713610089
Effective tax rate (%): -158.8235294117647
Interest coverage ratio: -1.504
COGS to revenue (%): 92.82029234737747
SG&A to revenue (%): 9.071367153912297
Free cash flow (dilution-adjusted): -496000000
Buyback yield (%): 0
Inventory turnover: 2.555029585798817
Receivables turnover: 1.0679522497704317
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -1.5269655620532814
FCF margin (%): -21.324161650902838
Revenue growth (%): -6.360708534621579
Rule of 40 score: -27.684870185524417
Financial ratios for IHD — annual report dated 2022-02-28
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 4.15
Shares outstanding: 17735861
Market cap (USD): 73603823.15
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IHD — annual report dated 2023-02-28
Total revenue: -16741162
Net income: -17042357
Capital expenditures: 0
Net tangible assets: 109847471
Owner earnings: -17042357
Return on net tangible assets (%): -15.514564736770318
Buffett classification: The Gruesome
Stock price: 3.57
Shares outstanding: 17735861
Book value: 109847471
P/B ratio: 0.5764085708445668
Market cap (USD): 63317023.769999996
Debt to equity: 0
Buyback yield (%): 0
Retained earnings: -82306470
Receivables turnover: -39.208029359482694
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IHD — annual report dated 2024-02-29
Total revenue: 10666113
Net income: 10392854
Capital expenditures: 0
Net tangible assets: 108965622
Owner earnings: 10392854
Return on net tangible assets (%): 9.537736589986153
Buffett classification: The Gruesome
Stock price: 3.91
P/E ratio: 6.672586424287303
Shares outstanding: 17735861
Book value: 108965622
P/B ratio: 0.6364137168876988
Market cap (USD): 69347216.51
Debt to equity: 0
COGS to revenue (%): 0
SG&A to revenue (%): 3.1476415072669863
Buyback yield (%): 0
Retained earnings: -75698535
Receivables turnover: 30.6180761281433
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IHD — quarterly report dated 2024-08-31
Capital expenditures: 0
Net tangible assets: 111172940
Buffett classification: The Gruesome
Stock price: 4.4
Shares outstanding: 17735861
Book value: 111172940
P/B ratio: 0.7019494887874693
Market cap (USD): 78037788.4
Debt to equity: 0
Buyback yield (%): 0
Retained earnings: -68328478
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IHD — quarterly report dated 2025-02-28
Capital expenditures: 0
Net tangible assets: 104183654
Buffett classification: The Gruesome
Stock price: 4.6
Shares outstanding: 17735861
Book value: 104183654
P/B ratio: 0.7830879170354305
Market cap (USD): 81584960.6
Debt to equity: 0
Buyback yield (%): 0
Retained earnings: -69068036
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IHD — annual report dated 2025-02-28
Total revenue: 9510181
Net income: 9234285
Capital expenditures: 0
Net tangible assets: 104183654
Owner earnings: 9234285
Return on net tangible assets (%): 8.86346815979405
Buffett classification: The Gruesome
Stock price: 4.6
P/E ratio: 8.835005698871107
Shares outstanding: 17735861
Book value: 104183654
P/B ratio: 0.7830879170354305
Market cap (USD): 81584960.6
Debt to equity: 0
COGS to revenue (%): 0
SG&A to revenue (%): 3.9801976429260386
Buyback yield (%): 0
Retained earnings: -69068036
Receivables turnover: 8.406893875371717
Capitalized R&D asset: 0
Revenue growth (%): -10.83742503009297
Rule of 40 score: -10.83742503009297
Financial ratios for IHD — quarterly report dated 2025-08-31
Capital expenditures: 0
Net tangible assets: 114092589
Buffett classification: The Gruesome
Stock price: 5.45
Shares outstanding: 17735861
Book value: 114092589
P/B ratio: 0.84721052696946
Market cap (USD): 96660442.45
Debt to equity: 0
Buyback yield (%): 0
Retained earnings: -54379370
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for INBS — annual report dated 2021-06-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 9456
Shares outstanding: 2391846
Market cap (USD): 22617295776
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for INBS — annual report dated 2022-06-30
Total revenue: 0
Gross profit: 0
Operating income: -8336876
Net income: -8306051
Capital expenditures: 380221
Operating cash flow: -3358034
Depreciation & amortization: 0
Net tangible assets: 6624922
Owner earnings: -8686272
Return on net tangible assets (%): -131.11508331720736
Buffett classification: The Gruesome
Stock price: 1588.8
Shares outstanding: 2391846
Book value: 6545771
P/B ratio: 580.5526842903608
Market cap (USD): 3800164924.7999997
Debt to equity: 0
Current ratio: 2.3306851829175317
Quick ratio: 2.3306851829175317
Interest coverage ratio: -1105.8331343679533
Free cash flow (dilution-adjusted): -3738255
Buyback yield (%): 0
Retained earnings: -31175853
Receivables turnover: 0
Capitalized R&D asset: 3853919
ROCI (R&D-adjusted, %): -49.9657991605771
Rule of 40 score: 0
Financial ratios for INBS — annual report dated 2023-06-30
Total revenue: 1256872
Gross profit: 326668
Operating income: -8436563
Net income: -10631720
Capital expenditures: 505123
Operating cash flow: -7377378
Depreciation & amortization: 966732
Net tangible assets: -1456417
Owner earnings: -10170111
Buffett classification: The Gruesome
Stock price: 333.6
Shares outstanding: 2391846
Book value: 3686998
P/B ratio: 216.41449916707307
Market cap (USD): 797919825.6
Debt to equity: 0.36226897871927244
Current ratio: 0.6564867085848409
Quick ratio: 0.4899402330342294
Interest coverage ratio: -37.74174398525504
COGS to revenue (%): 74.0094456714765
R&D to revenue (%): 40.371971051944826
SG&A to revenue (%): 638.6253333672801
Free cash flow (dilution-adjusted): -8142501
Buyback yield (%): 0
Retained earnings: -41807573
Inventory turnover: 0.9492778396317202
Receivables turnover: 1.5085529379569929
Capitalized R&D asset: 3089549.73
ROCI (R&D-adjusted, %): -124.10487241854125
Rosenberg metric: 0.08476254949831587
FCF margin (%): -647.8385229363054
Rule of 40 score: -647.8385229363054
Financial ratios for INBS — annual report dated 2024-06-30
Total revenue: 3111781
Gross profit: 1425626
Operating income: -10283174
Net income: -10156759
Capital expenditures: 221426
Operating cash flow: -9571569
Depreciation & amortization: 1213085
Net tangible assets: 3957324
Owner earnings: -9165100
Return on net tangible assets (%): -231.5984235811877
Buffett classification: The Gruesome
Stock price: 19.2
Shares outstanding: 2391846
Book value: 8183191
P/B ratio: 5.611923661564297
Market cap (USD): 45923443.199999996
Debt to equity: 0.10649146524870311
Current ratio: 1.5657055665724224
Quick ratio: 1.423057412645235
Interest coverage ratio: -61.52431494555462
COGS to revenue (%): 54.18617184178449
R&D to revenue (%): 53.78932514852427
SG&A to revenue (%): 297.530449604262
Free cash flow (dilution-adjusted): -10023491
Buyback yield (%): 0
Retained earnings: -51964332
Inventory turnover: 2.1685849033550815
Receivables turnover: 3.180648399138139
Capitalized R&D asset: 3285573.35
ROCI (R&D-adjusted, %): -91.4530362387234
Rosenberg metric: 2.1657588131424608
FCF margin (%): -322.1142811785277
Revenue growth (%): 147.58137662387261
Rule of 40 score: -174.53290455465506
Financial ratios for INBS — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 17.3
Shares outstanding: 2391846
Market cap (USD): 41378935.800000004
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for INBS — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 14
Shares outstanding: 2391846
Market cap (USD): 33485844
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for INBS — quarterly report dated 2025-03-31
Total revenue: 728867
Gross profit: 341368
Operating income: -2560329
Net income: -2543526
Capital expenditures: 14385
Operating cash flow: -2755388
Depreciation & amortization: 301978
Net tangible assets: 1309626
Owner earnings: -2255933
Return on net tangible assets (%): -172.2578049000249
Buffett classification: The Gruesome
Stock price: 14.4
Shares outstanding: 2391846
Book value: 4943766
P/B ratio: 6.966871490276846
Market cap (USD): 34442582.4
Debt to equity: 0.10339931137517432
Current ratio: 1.1189527176169407
Quick ratio: 0.9692089952972854
Interest coverage ratio: -323.3146861977522
COGS to revenue (%): 53.87073361806749
R&D to revenue (%): 49.16548560985749
SG&A to revenue (%): 331.2866407725964
Free cash flow (dilution-adjusted): -2781773
Buyback yield (%): 0
Retained earnings: -59442961
Inventory turnover: 0.5744738751814223
Receivables turnover: 0.7067629875639379
Capitalized R&D asset: 358351
ROCI (R&D-adjusted, %): -43.16131550851388
FCF margin (%): -381.6571473259182
Rule of 40 score: -381.6571473259182
Financial ratios for INBS — quarterly report dated 2025-06-30
Total revenue: 843884
Gross profit: 335577
Operating income: -2881554
Net income: -3090104
Capital expenditures: 208517
Operating cash flow: -2209957
Depreciation & amortization: 306172
Net tangible assets: -794183
Owner earnings: -2992449
Buffett classification: The Gruesome
Stock price: 17.2
Shares outstanding: 2391846
Book value: 2813824
P/B ratio: 14.620584372014738
Market cap (USD): 41139751.199999996
Debt to equity: 0.1001501870763772
Current ratio: 0.773423713255047
Quick ratio: 0.6547150358220017
Interest coverage ratio: -286.40830931318953
COGS to revenue (%): 60.23422650506468
R&D to revenue (%): 69.02204568400396
SG&A to revenue (%): 322.1093183423314
Free cash flow (dilution-adjusted): -2430474
Buyback yield (%): 0
Retained earnings: -62533065
Inventory turnover: 0.8002125264674166
Receivables turnover: 0.5277213748406143
Capitalized R&D asset: 822561.17
ROCI (R&D-adjusted, %): -70.20904884767025
Rosenberg metric: -0.016160133500394865
FCF margin (%): -288.01043745348886
Revenue growth (%): 15.780245229925349
Rule of 40 score: -272.2301922235635
Financial ratios for INBS — annual report dated 2025-06-30
Total revenue: 3052532
Gross profit: 1246859
Operating income: -10424545
Net income: -10568733
Capital expenditures: 231838
Operating cash flow: -9677313
Depreciation & amortization: 1213749
Net tangible assets: -794183
Owner earnings: -9586822
Buffett classification: The Gruesome
Stock price: 17.2
Shares outstanding: 2391846
Book value: 2813824
P/B ratio: 14.620584372014738
Market cap (USD): 41139751.199999996
Debt to equity: 0.1001501870763772
Current ratio: 0.773423713255047
Quick ratio: 0.6547150358220017
Interest coverage ratio: -171.2029068812613
COGS to revenue (%): 59.1532865175533
R&D to revenue (%): 78.5090213632486
SG&A to revenue (%): 291.03436098294793
Free cash flow (dilution-adjusted): -10147196
Buyback yield (%): 0
Retained earnings: -62533065
Inventory turnover: 2.8426170666624686
Receivables turnover: 1.9088955161905787
Capitalized R&D asset: 3685412.94
ROCI (R&D-adjusted, %): -145.10506006077574
Rosenberg metric: -0.10680269995447501
FCF margin (%): -332.4189885642476
Revenue growth (%): -1.9040221660843097
Rule of 40 score: -334.32301073033193
Financial ratios for INBS — quarterly report dated 2025-09-30
Total revenue: 1111797
Gross profit: 518291
Operating income: -2737813
Net income: -2983006
Capital expenditures: 70401
Operating cash flow: -2846825
Depreciation & amortization: 303378
Net tangible assets: 147924
Owner earnings: -2750029
Return on net tangible assets (%): -1859.0823666206973
Buffett classification: The Gruesome
Stock price: 10.2
Shares outstanding: 2391846
Book value: 3426929
P/B ratio: 7.119152220544983
Market cap (USD): 24396829.2
Debt to equity: 0.5695633028872206
Current ratio: 0.8858758287610967
Quick ratio: 0.7617810407354771
Interest coverage ratio: -701.463745836536
COGS to revenue (%): 53.382586929088674
R&D to revenue (%): 43.72821657191016
SG&A to revenue (%): 239.23647932131496
Free cash flow (dilution-adjusted): -2929226
Buyback yield (%): 0
Retained earnings: -65516071
Inventory turnover: 0.9448069572747808
Receivables turnover: 0.6771466941960004
Capitalized R&D asset: 994677.0499999999
ROCI (R&D-adjusted, %): -45.676539482774665
Rosenberg metric: 0.31369041283096355
FCF margin (%): -263.46770138793323
Revenue growth (%): 31.747609861070952
Rule of 40 score: -231.7200915268623
Financial ratios for INBS — quarterly report dated 2025-12-31
Total revenue: 896774
Gross profit: 459739
Operating income: -2608591
Net income: -2677590
Capital expenditures: 68232
Operating cash flow: -1567515
Depreciation & amortization: 281896
Net tangible assets: 7823693
Owner earnings: -2463926
Return on net tangible assets (%): -31.493132463147518
Buffett classification: The Gruesome
Stock price: 9.53
Shares outstanding: 2391846
Book value: 10889811
P/B ratio: 2.0931761239933366
Market cap (USD): 22794292.38
Debt to equity: 0.17673245201408913
Current ratio: 2.3745097997148954
Quick ratio: 2.2593901866520416
Interest coverage ratio: -46.40877795370848
COGS to revenue (%): 48.73412922319336
R&D to revenue (%): 58.22124637868627
SG&A to revenue (%): 260.60534761266496
Free cash flow (dilution-adjusted): -1697322
Buyback yield (%): 0
Retained earnings: -68193661
Inventory turnover: 0.7404285670720344
Receivables turnover: 0.0865283395282139
Capitalized R&D asset: 1040060.01
ROCI (R&D-adjusted, %): -19.28906194309692
Rosenberg metric: -0.12043548642550224
FCF margin (%): -189.269760274049
Revenue growth (%): -19.340131336925715
Rule of 40 score: -208.6098916109747
Financial ratios for IREN.SW — annual report dated 2021-12-31
Capital expenditures: 5101098.9010989005
Buffett classification: The Gruesome
Stock price: 102.58241758241758
Shares outstanding: 12757862
Market cap (USD): 1308732327.142857
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IREN.SW — annual report dated 2022-12-31
Total revenue: 247334782.60869566
Gross profit: 219721739.13043478
Operating income: 54159782.60869565
Net income: 165027173.91304347
Capital expenditures: 13111956.521739129
Operating cash flow: 59296739.13043478
Depreciation & amortization: 4018478.260869565
Net tangible assets: 1153833695.6521738
Owner earnings: 155933695.6521739
Return on net tangible assets (%): 13.51439953953126
Capex to operating income (%): 24.209765789632126
Buffett classification: The Great
Stock price: 100.79347826086956
P/E ratio: 7.7921063280750875
Shares outstanding: 12757862
Book value: 1162690217.3913043
P/B ratio: 1.1059775569775867
Market cap (USD): 1285909286.152174
Debt to equity: 0.29822142239465255
Current ratio: 0.1709951239816852
Quick ratio: 0.1102158530058869
Effective tax rate (%): 14.686363866240356
Interest coverage ratio: 25.43491577335375
COGS to revenue (%): 11.164237875085695
SG&A to revenue (%): 5.023555469615202
Free cash flow (dilution-adjusted): 45909782.60869565
Buyback yield (%): 0.2512179371746451
Retained earnings: 1161211956.521739
Inventory turnover: 1.553381435734377
Receivables turnover: 14.669159360495101
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.7512252632339727
FCF margin (%): 18.561797950322568
Rule of 40 score: 18.561797950322568
Financial ratios for IREN.SW — annual report dated 2023-12-31
Total revenue: 275630952.3809524
Gross profit: 245282142.85714287
Operating income: 54736904.76190476
Net income: -6420238.095238095
Capital expenditures: 6713095.238095239
Operating cash flow: 60133333.333333336
Depreciation & amortization: 4860714.285714285
Net tangible assets: 1214822619.047619
Owner earnings: -8272619.0476190485
Return on net tangible assets (%): -0.6809734127361333
Capex to operating income (%): 12.264294569259881
Buffett classification: The Great
Stock price: 108.83333333333334
Shares outstanding: 12757862
Book value: 1225289285.7142859
P/B ratio: 1.133185986244259
Market cap (USD): 1388480647.6666667
Debt to equity: 0.3517148039870079
Current ratio: 0.12422471521411452
Quick ratio: 0.09559477624848652
Interest coverage ratio: 15.045484293193716
COGS to revenue (%): 11.010668163952834
Free cash flow (dilution-adjusted): 53067857.14285714
Buyback yield (%): 0
Retained earnings: 1229384523.8095238
Inventory turnover: 2.750350631136045
Receivables turnover: 15.41375407762466
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.5758003729863326
FCF margin (%): 19.253228523301512
Revenue growth (%): 11.440432871515558
Rule of 40 score: 30.69366139481707
Financial ratios for IREN.SW — annual report dated 2024-12-31
Total revenue: 169674444.44444445
Gross profit: 145156666.66666666
Operating income: 51781111.11111111
Net income: 273920000
Capital expenditures: 2348888.888888889
Operating cash flow: 61692222.222222224
Depreciation & amortization: 2548888.888888889
Net tangible assets: 1488335555.5555556
Owner earnings: 274120000
Return on net tangible assets (%): 18.417889633610102
Capex to operating income (%): 4.536188657382572
Buffett classification: The Great
Stock price: 119.55555555555554
P/E ratio: 5.5683165855399785
Shares outstanding: 12757862
Book value: 1488338888.888889
P/B ratio: 1.0248158470479765
Market cap (USD): 1525273279.111111
Debt to equity: 0.3702860384992963
Current ratio: 0.03072740139297553
Quick ratio: 0.02081393472134282
Effective tax rate (%): 7.9957750000933085
Interest coverage ratio: 7.824546675621222
COGS to revenue (%): 14.44989424191425
Free cash flow (dilution-adjusted): 59227777.777777776
Buyback yield (%): 0
Retained earnings: 1490781111.1111112
Inventory turnover: 4.605719056564392
Receivables turnover: 52.29691780821918
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.9204650635222924
FCF margin (%): 34.906716784430316
Revenue growth (%): -38.44144027411855
Rule of 40 score: -3.5347234896882327
Financial ratios for IREN.SW — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 1488335555.5555556
Buffett classification: The Gruesome
Stock price: 119.55555555555554
Shares outstanding: 12757862
Book value: 1488338888.888889
P/B ratio: 1.0248158470479765
Market cap (USD): 1525273279.111111
Debt to equity: 0.3702860384992963
Current ratio: 0.03072740139297553
Quick ratio: 0.02081393472134282
Buyback yield (%): 0
Retained earnings: 1490781111.1111112
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IREN.SW — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: 1731257500
Buffett classification: The Gruesome
Stock price: 155.725
Shares outstanding: 12757862
Book value: 1731258750
P/B ratio: 1.1475569783835027
Market cap (USD): 1986718059.9499998
Debt to equity: 0.4252686087507139
Current ratio: 0.08012551901774367
Quick ratio: 0.05635625674961756
Buyback yield (%): 0
Retained earnings: 1735935000
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IVDA — annual report dated 2021-12-31
Capital expenditures: 24513
Buffett classification: The Gruesome
Stock price: 140.8
Shares outstanding: 11594027
Market cap (USD): 1632439001.6000001
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IVDA — annual report dated 2022-12-31
Total revenue: 4468279
Gross profit: 963501
Operating income: -3329319
Net income: -3345270
Capital expenditures: 14165
Operating cash flow: -5408720
Depreciation & amortization: 17801
Net tangible assets: 7569750
Owner earnings: -3341634
Return on net tangible assets (%): -44.14457544833053
Buffett classification: The Gruesome
Stock price: 4.48
Shares outstanding: 11594027
Book value: 7569750
P/B ratio: 6.861685123022558
Market cap (USD): 51941240.96000001
Debt to equity: 0.0864748505564913
Current ratio: 4.548191143681179
Quick ratio: 4.297794481352114
Interest coverage ratio: -62.43682838549969
COGS to revenue (%): 78.43686573734541
SG&A to revenue (%): 96.07323087927142
Free cash flow (dilution-adjusted): -5543466
Buyback yield (%): 0
Retained earnings: -44706671
Inventory turnover: 6.657127661595153
Receivables turnover: 3.6544659725686803
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -42.9006874018591
FCF margin (%): -124.062664842549
Rule of 40 score: -124.062664842549
Financial ratios for IVDA — annual report dated 2023-12-31
Total revenue: 6495865
Gross profit: 1067604
Operating income: -4040875
Net income: -4142666
Capital expenditures: 85593
Operating cash flow: -3333360
Depreciation & amortization: 19753
Net tangible assets: 4648480
Owner earnings: -4208506
Return on net tangible assets (%): -90.53509964547551
Buffett classification: The Gruesome
Stock price: 5.04
Shares outstanding: 11594027
Book value: 4648480
P/B ratio: 12.570538343716656
Market cap (USD): 58433896.08
Debt to equity: 0.07502904175128214
Current ratio: 3.564867269716502
Quick ratio: 3.36910329767115
Interest coverage ratio: -557.0547284256961
COGS to revenue (%): 83.56486780436477
R&D to revenue (%): 12.271067825455116
SG&A to revenue (%): 66.37094520899063
Free cash flow (dilution-adjusted): -3523553
Buyback yield (%): 0
Retained earnings: -49195897
Inventory turnover: 16.727303822627615
Receivables turnover: 23.112926927332957
Capitalized R&D asset: 797112
ROCI (R&D-adjusted, %): -64.44601431763526
FCF margin (%): -54.24301459466907
Revenue growth (%): 45.377336553961825
Rule of 40 score: -8.865678040707245
Financial ratios for IVDA — quarterly report dated 2024-09-30
Capital expenditures: 339339
Buffett classification: The Gruesome
Stock price: 1.67
Shares outstanding: 11594027
Market cap (USD): 19362025.09
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IVDA — annual report dated 2024-12-31
Total revenue: 6020639
Gross profit: 1301634
Operating income: -4070303
Net income: -3980820
Capital expenditures: 2608
Operating cash flow: -4419748
Depreciation & amortization: 31805
Net tangible assets: 2505439
Owner earnings: -3951623
Return on net tangible assets (%): -157.72178049435647
Buffett classification: The Gruesome
Stock price: 4.94
Shares outstanding: 11594027
Book value: 2505439
P/B ratio: 22.860062998939508
Market cap (USD): 57274493.38
Debt to equity: 0.36928458445805307
Current ratio: 2.1874054839028343
Quick ratio: 2.1229463216021314
Interest coverage ratio: -155.45594469694078
COGS to revenue (%): 78.38046758824106
R&D to revenue (%): 6.035073685700139
SG&A to revenue (%): 83.19028926995955
Free cash flow (dilution-adjusted): -4544956
Buyback yield (%): 0
Retained earnings: -53176717
Inventory turnover: 31.859337024034566
Receivables turnover: 4.712330986549366
Capitalized R&D asset: 897415.04
ROCI (R&D-adjusted, %): -108.3283441500605
Rosenberg metric: 0.29359738656550144
FCF margin (%): -75.48959504132368
Revenue growth (%): -7.315823219848319
Rule of 40 score: -82.80541826117201
Financial ratios for IVDA — quarterly report dated 2024-12-31
Capital expenditures: 0
Depreciation & amortization: 7999
Buffett classification: The Gruesome
Stock price: 4.94
Shares outstanding: 11594027
Market cap (USD): 57274493.38
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IVDA — quarterly report dated 2025-03-31
Total revenue: 1474576
Gross profit: 288211
Operating income: -835559
Net income: -793672
Capital expenditures: 109
Operating cash flow: -125966
Depreciation & amortization: 7285
Net tangible assets: 1700887
Owner earnings: -786496
Return on net tangible assets (%): -46.24034400874367
Buffett classification: The Gruesome
Stock price: 2.26
Shares outstanding: 11594027
Book value: 1700887
P/B ratio: 15.40519800551124
Market cap (USD): 26202501.019999996
Debt to equity: 0.6511837647062974
Current ratio: 1.8013722002240675
Quick ratio: 1.7083123091790744
Interest coverage ratio: -144.16131815044858
COGS to revenue (%): 80.45465272729245
R&D to revenue (%): 2.2379314460563577
SG&A to revenue (%): 73.97177222469374
Free cash flow (dilution-adjusted): -125966
Buyback yield (%): 0
Retained earnings: -53970389
Inventory turnover: 5.4513435771132395
Receivables turnover: 1.7988118328758769
Capitalized R&D asset: 33000
ROCI (R&D-adjusted, %): -36.60154448665951
FCF margin (%): -8.542523410119248
Rule of 40 score: -8.542523410119248
Financial ratios for IVDA — quarterly report dated 2025-06-30
Total revenue: 1527907
Gross profit: 444769
Operating income: -532360
Net income: -564249
Capital expenditures: 1310
Operating cash flow: -1332108
Depreciation & amortization: 6056
Net tangible assets: 1480557
Owner earnings: -559503
Return on net tangible assets (%): -37.790034426232836
Buffett classification: The Gruesome
Stock price: 2.03
Shares outstanding: 11594027
Book value: 1480557
P/B ratio: 15.896635394652145
Market cap (USD): 23535874.81
Debt to equity: 0.8095149325557881
Current ratio: 1.7001189487230284
Quick ratio: 1.5856963536264794
Interest coverage ratio: -43.938593595245955
COGS to revenue (%): 70.89030942328296
R&D to revenue (%): 3.3706239974029835
SG&A to revenue (%): 60.58150136101216
Free cash flow (dilution-adjusted): -1333309
Buyback yield (%): 0
Retained earnings: -54534638
Inventory turnover: 3.939758115849777
Receivables turnover: 1.1181522726291424
Capitalized R&D asset: 73610
ROCI (R&D-adjusted, %): -24.700907415593885
Rosenberg metric: 4.7441818181818185
FCF margin (%): -87.26375361851211
Revenue growth (%): 3.6167006651403524
Rule of 40 score: -83.64705295337176
Financial ratios for IVDA — quarterly report dated 2025-09-30
Total revenue: 1651787
Gross profit: 517277
Operating income: -214303
Net income: -221304
Capital expenditures: 1201
Operating cash flow: -317006
Depreciation & amortization: 2721
Net tangible assets: 3768242
Owner earnings: -219784
Return on net tangible assets (%): -5.8325341100704255
Buffett classification: The Gruesome
Stock price: 1.34
Shares outstanding: 11594027
Book value: 3768242
P/B ratio: 4.122876444771859
Market cap (USD): 15535996.180000002
Debt to equity: 0.20413630547082698
Current ratio: 3.4763139986288105
Quick ratio: 3.3193337109073
Interest coverage ratio: -18.515897701745292
COGS to revenue (%): 68.68379518666752
R&D to revenue (%): 1.5589177054910834
SG&A to revenue (%): 42.73129646861248
Free cash flow (dilution-adjusted): -315805
Buyback yield (%): 0
Retained earnings: -54755942
Inventory turnover: 4.583582475476333
Receivables turnover: 1.2474922323776552
Capitalized R&D asset: 71145
ROCI (R&D-adjusted, %): -5.272970290379286
Rosenberg metric: 1.4079223300970873
FCF margin (%): -19.118990523596565
Revenue growth (%): 8.107823316471487
Rule of 40 score: -11.011167207125078
Financial ratios for IVDA — annual report dated 2025-12-31
Total revenue: 5280312
Gross profit: 1272872
Operating income: -3226896
Net income: -3198112
Capital expenditures: 0
Operating cash flow: -2027501
Depreciation & amortization: 21584
Net tangible assets: 4779762
Owner earnings: -3176528
Return on net tangible assets (%): -66.45786965961904
Buffett classification: The Gruesome
Stock price: 0.84
Shares outstanding: 11594027
Book value: 4779762
P/B ratio: 2.0375455263253692
Market cap (USD): 9738982.68
Debt to equity: 0.14843165831269423
Current ratio: 4.857253892551992
Quick ratio: 4.671063180387788
Interest coverage ratio: -88.38631570297734
COGS to revenue (%): 75.89400020301831
R&D to revenue (%): 3.234657346005312
SG&A to revenue (%): 81.98318584204873
Free cash flow (dilution-adjusted): -2403501
Buyback yield (%): 0
Retained earnings: -56374829
Inventory turnover: 16.98370048907009
Receivables turnover: 20.570052863470448
Capitalized R&D asset: 677291.46
ROCI (R&D-adjusted, %): -59.951631075095335
Rosenberg metric: -0.07915783679647723
FCF margin (%): -45.51816256312127
Revenue growth (%): -12.296485472721418
Rule of 40 score: -57.814648035842694
Financial ratios for IVDA — quarterly report dated 2025-12-31
Total revenue: 626042
Gross profit: 22614
Operating income: -1644675
Net income: -1618887
Capital expenditures: 0
Operating cash flow: -252421
Depreciation & amortization: 5522
Net tangible assets: 4779762
Owner earnings: -1613365
Return on net tangible assets (%): -33.75408650054124
Buffett classification: The Gruesome
Stock price: 0.84
Shares outstanding: 11594027
Book value: 4779762
P/B ratio: 2.0375455263253692
Market cap (USD): 9738982.68
Debt to equity: 0.14843165831269423
Current ratio: 4.857253892551992
Quick ratio: 4.671063180387788
Interest coverage ratio: -234.21745941327256
COGS to revenue (%): 96.38778228936717
R&D to revenue (%): 9.671875049916778
SG&A to revenue (%): 256.65035253225824
Free cash flow (dilution-adjusted): -252421
Buyback yield (%): 0
Retained earnings: -56374829
Inventory turnover: 2.5573534273048595
Receivables turnover: 2.4388174476721765
Capitalized R&D asset: 94797.5
ROCI (R&D-adjusted, %): -31.017443896986062
Rosenberg metric: -19.21021359223301
FCF margin (%): -40.320138265483784
Revenue growth (%): -62.09910842015345
Rule of 40 score: -102.41924668563723
Financial ratios for JFN.SW — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 129.6813186813187
Shares outstanding: 5834761
Market cap (USD): 756659500.6703297
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JFN.SW — annual report dated 2022-12-31
Total revenue: 193895652.17391303
Gross profit: 57123913.04347826
Operating income: 33535869.56521739
Net income: 48243478.26086956
Capital expenditures: 31321739.13043478
Operating cash flow: 94901086.95652173
Depreciation & amortization: 45980434.782608695
Net tangible assets: 678265217.3913044
Owner earnings: 62902173.91304347
Return on net tangible assets (%): 9.273979012955042
Capex to operating income (%): 93.39772469451917
Buffett classification: The Gruesome
Stock price: 118.52173913043478
P/E ratio: 14.33449755407354
Shares outstanding: 5834761
Book value: 696053260.8695652
P/B ratio: 0.9935245763614416
Market cap (USD): 691546021.1304348
Debt to equity: 0.16007957911766496
Current ratio: 1.1084997987145495
Quick ratio: 1.070991296139484
Effective tax rate (%): 15.910727141828653
Interest coverage ratio: 74.7046004842615
COGS to revenue (%): 70.53883756390708
SG&A to revenue (%): 8.651000089694143
Free cash flow (dilution-adjusted): 63295652.17391304
Buyback yield (%): 0.5323610615404077
Retained earnings: 683797826.0869565
Inventory turnover: 46.56920799407846
Receivables turnover: 7.830384969931083
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.001847026274727
FCF margin (%): 32.644183334828234
Rule of 40 score: 32.644183334828234
Financial ratios for JFN.SW — annual report dated 2023-12-31
Total revenue: 292190476.1904762
Gross profit: 127858333.33333334
Operating income: 91788095.23809524
Net income: 94782142.85714287
Capital expenditures: 43759523.80952381
Operating cash flow: 114678571.42857143
Depreciation & amortization: 47340476.190476194
Net tangible assets: 770139285.7142857
Owner earnings: 98363095.23809522
Return on net tangible assets (%): 12.772117597775292
Capex to operating income (%): 47.67450909185236
Buffett classification: The Good
Stock price: 171.52380952380955
P/E ratio: 10.558955560747076
Shares outstanding: 5834761
Book value: 786395238.0952382
P/B ratio: 1.2726430500838666
Market cap (USD): 1000800434.3809525
Debt to equity: 0.1774235056890089
Current ratio: 1.3634340696908294
Quick ratio: 1.3238522643925361
Effective tax rate (%): 20.425174657431562
Interest coverage ratio: 379.8128078817734
COGS to revenue (%): 56.24144393741852
SG&A to revenue (%): 6.585316166883964
Free cash flow (dilution-adjusted): 70092857.14285715
Buyback yield (%): 4.975184358054903
Retained earnings: 818153571.4285715
Inventory turnover: 43.35395728643216
Receivables turnover: 12.580860115843969
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 9.50183808351295
FCF margin (%): 23.988754889178622
Revenue growth (%): 50.69470249307007
Rule of 40 score: 74.68345738224869
Financial ratios for JFN.SW — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 781063333.3333334
Buffett classification: The Gruesome
Stock price: 179.95555555555555
Shares outstanding: 5834761
Book value: 798503333.3333334
P/B ratio: 1.314957137255393
Market cap (USD): 1049997657.2888888
Debt to equity: 0.16927501868078193
Current ratio: 2.2523064580826313
Quick ratio: 2.2062274368231045
Buyback yield (%): 0
Retained earnings: 806755555.5555556
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JFN.SW — annual report dated 2024-12-31
Total revenue: 289445555.5555555
Gross profit: 118602222.22222222
Operating income: 79602222.22222222
Net income: 84961111.1111111
Capital expenditures: 48537777.777777776
Operating cash flow: 126633333.33333333
Depreciation & amortization: 43413333.333333336
Net tangible assets: 781063333.3333334
Owner earnings: 79836666.66666667
Return on net tangible assets (%): 10.221535598905765
Capex to operating income (%): 60.97540548840066
Buffett classification: The Good
Stock price: 179.95555555555555
P/E ratio: 12.3585678618976
Shares outstanding: 5834761
Book value: 798503333.3333334
P/B ratio: 1.314957137255393
Market cap (USD): 1049997657.2888888
Debt to equity: 0.16927501868078193
Current ratio: 2.2523064580826313
Quick ratio: 2.2062274368231045
Effective tax rate (%): 20.77561465855756
Interest coverage ratio: 244.51194539249147
COGS to revenue (%): 59.02434155723012
SG&A to revenue (%): 7.245269691862988
Free cash flow (dilution-adjusted): 74836666.66666667
Buyback yield (%): 0
Retained earnings: 806755555.5555556
Inventory turnover: 41.82780195865071
Receivables turnover: 15.527269476068424
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 8.273646331126011
FCF margin (%): 25.855179058813597
Revenue growth (%): -0.9394285093437711
Rule of 40 score: 24.915750549469827
Financial ratios for JFN.SW — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: 895231250
Buffett classification: The Gruesome
Stock price: 244.33749999999998
Shares outstanding: 5834761
Book value: 914762500
P/B ratio: 1.5584929594703543
Market cap (USD): 1425650915.8374999
Debt to equity: 0
Current ratio: 2.5817076642274652
Quick ratio: 2.5095530735611784
Buyback yield (%): 0
Retained earnings: 902186250
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JUBLPHARMA.NS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 4.933403666095213
Shares outstanding: 158387168
Market cap (USD): 781387835.2736384
Buyback yield (%): 0
Retained earnings: 617831596.9932745
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JUBLPHARMA.NS — annual report dated 2023-03-31
Total revenue: 757527405.6029233
Gross profit: 486784409.25700366
Operating income: 28002436.05359318
Net income: -7429963.459196103
Capital expenditures: 96942752.7405603
Operating cash flow: 80475030.45066991
Depreciation & amortization: 67478684.53105968
Net tangible assets: 246004872.10718638
Owner earnings: -36894031.66869672
Return on net tangible assets (%): -14.997276823290589
Capex to operating income (%): 346.1939973901696
Buffett classification: The Gruesome
Stock price: 3.32095006090134
Shares outstanding: 158387168
Book value: 656735688.18514
P/B ratio: 0.8009247626989132
Market cap (USD): 525995875.2155907
Debt to equity: 0.6819244037241738
Current ratio: 2.1227713834348902
Quick ratio: 1.343883999097269
Effective tax rate (%): 333.45323741007195
Interest coverage ratio: 1.363582443653618
COGS to revenue (%): 35.74035663177528
SG&A to revenue (%): 6.185583586577268
Free cash flow (dilution-adjusted): -19183922.046285022
Buyback yield (%): 0.09262633826474709
Retained earnings: 552594397.0767357
Inventory turnover: 1.6101412531691415
Receivables turnover: 6.470349563046192
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.4498364289291694
FCF margin (%): -2.532439342048141
Rule of 40 score: -2.532439342048141
Financial ratios for JUBLPHARMA.NS — annual report dated 2024-03-31
Total revenue: 796834152.7761122
Gross profit: 506379661.82995564
Operating income: 62729344.046048686
Net income: 9245712.915217651
Capital expenditures: 106487588.4398609
Operating cash flow: 116476795.77887037
Depreciation & amortization: 45796858.1364672
Net tangible assets: 231046888.11608106
Owner earnings: -51445017.38817604
Return on net tangible assets (%): -22.266050760367467
Capex to operating income (%): 169.75721659338558
Buffett classification: The Gruesome
Stock price: 6.768234165067179
P/E ratio: 115.94578499202723
Shares outstanding: 158387168
Book value: 650089938.8415877
P/B ratio: 1.6490048187425612
Market cap (USD): 1072001441.765835
Debt to equity: 0.6758775894191217
Current ratio: 2.0519322392800423
Quick ratio: 1.3692429857067228
Effective tax rate (%): 57.360703812316714
Interest coverage ratio: 2.040171606864275
COGS to revenue (%): 36.45105947507826
SG&A to revenue (%): 6.630748856248496
Free cash flow (dilution-adjusted): 7806691.449814126
Buyback yield (%): 0.30650758024407426
Retained earnings: 544393812.2076987
Inventory turnover: 1.8781792803970223
Receivables turnover: 7.254940495687301
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.41539417154097
FCF margin (%): 0.9797134601492896
Revenue growth (%): 5.18882180135837
Rule of 40 score: 6.168535261507659
Financial ratios for JUBLPHARMA.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 285140946.0105112
Buffett classification: The Gruesome
Stock price: 13.687290969899667
Shares outstanding: 158387168
Book value: 707955088.389871
P/B ratio: 3.0621875453214105
Market cap (USD): 2167891254.3143816
Debt to equity: 0.5197233001518475
Current ratio: 1.7987466611875897
Quick ratio: 1.2021265666735155
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JUBLPHARMA.NS — quarterly report dated 2024-12-31
Total revenue: 211411586.43198505
Gross profit: 144457395.9668959
Operating income: 22858141.974589113
Net income: 11761277.538174612
Capital expenditures: 0
Depreciation & amortization: 10642265.998368107
Owner earnings: 22403543.53654272
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 12.827835412052686
P/E ratio: 43.18758136372646
Shares outstanding: 158387168
Market cap (USD): 2031764522.485138
Effective tax rate (%): 22.83524904214559
Interest coverage ratio: 3.526978417266187
COGS to revenue (%): 31.670066714451124
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JUBLPHARMA.NS — annual report dated 2025-03-31
Total revenue: 840787935.4687865
Gross profit: 569920505.026888
Operating income: 94119710.07715687
Net income: 98129530.04442365
Capital expenditures: 129833995.79144259
Operating cash flow: 125333177.46083702
Depreciation & amortization: 43090951.601589896
Net tangible assets: 305962122.98339957
Owner earnings: 11386485.85457097
Return on net tangible assets (%): 3.7215344643130095
Capex to operating income (%): 137.9455968202708
Buffett classification: The Gruesome
Stock price: 10.410666355467383
P/E ratio: 16.803463343693675
Shares outstanding: 158387168
Book value: 729319616.5536591
P/B ratio: 2.2608962156087054
Market cap (USD): 1648915961.03536
Debt to equity: 0.43775847145192825
Current ratio: 1.652591702855031
Quick ratio: 1.1309248821953246
Effective tax rate (%): 14.715480318172547
Interest coverage ratio: 3.3503953391593835
COGS to revenue (%): 32.215903560851494
SG&A to revenue (%): 5.825836681914879
Free cash flow (dilution-adjusted): -5588028.992284311
Buyback yield (%): 0.03970271984271729
Retained earnings: 619803600.6546644
Inventory turnover: 2.051895147006731
Receivables turnover: 8.067414469994391
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.601163163957023
FCF margin (%): -0.6646181226623656
Revenue growth (%): 5.516051557220846
Rule of 40 score: 4.851433434558481
Financial ratios for JUBLPHARMA.NS — quarterly report dated 2025-03-31
Total revenue: 223965396.30582184
Gross profit: 150771568.85667524
Operating income: 29249473.93032499
Net income: 17956511.57353285
Capital expenditures: 0
Depreciation & amortization: 11129296.235679213
Net tangible assets: 305962122.98339957
Owner earnings: 29085807.809212063
Return on net tangible assets (%): 9.50634265627388
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 10.410666355467383
P/E ratio: 22.95707540803462
Shares outstanding: 158387168
Book value: 729319616.5536591
P/B ratio: 2.2608962156087054
Market cap (USD): 1648915961.03536
Debt to equity: 0.43775847145192825
Current ratio: 1.652591702855031
Quick ratio: 1.1309248821953246
Effective tax rate (%): 26.553398058252426
Interest coverage ratio: 4.747628083491461
COGS to revenue (%): 32.680864390855
Buyback yield (%): 0
Retained earnings: 619803600.6546644
Inventory turnover: 0.5544633368756643
Receivables turnover: 2.1489624228827817
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.3622047244094486
Revenue growth (%): 5.938089811305387
Rule of 40 score: 5.938089811305387
Financial ratios for JUBLPHARMA.NS — quarterly report dated 2025-06-30
Total revenue: 219857243.15469226
Gross profit: 147519307.27825886
Operating income: 22408144.161011
Net income: 12040720.805054998
Capital expenditures: 0
Depreciation & amortization: 11479054.528434357
Owner earnings: 23519775.333489355
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 14.105429440674001
P/E ratio: 53.50092776263963
Shares outstanding: 158387168
Market cap (USD): 2234119022.532179
Effective tax rate (%): 33.6139896373057
Interest coverage ratio: 3.9081632653061225
COGS to revenue (%): 32.90223002820799
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -1.8342803035161486
Rule of 40 score: -1.8342803035161486
Financial ratios for JUBLPHARMA.NS — quarterly report dated 2025-12-31
Total revenue: 235724629.6090008
Gross profit: 155931825.77698565
Operating income: 18803609.22357135
Net income: 6227024.618469422
Capital expenditures: 0
Depreciation & amortization: 13445471.76116743
Owner earnings: 19672496.37963685
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 11.956110059039768
P/E ratio: 39.46385990880721
Shares outstanding: 158387168
Market cap (USD): 1893694412.5476215
Effective tax rate (%): 40.256959314775166
Interest coverage ratio: 3.0089126559714794
COGS to revenue (%): 33.85000708851189
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 7.217131547103134
Rule of 40 score: 7.217131547103134
Financial ratios for KIDZ — quarterly report dated 2025-06-30
Total revenue: 725648
Gross profit: 322718
Operating income: -1699033
Net income: -3866169
Capital expenditures: 0
Operating cash flow: -336511
Depreciation & amortization: 92201
Net tangible assets: -3070775
Owner earnings: -3773968
Buffett classification: The Gruesome
Stock price: 1470
Shares outstanding: 2042088
Book value: 2704703
P/B ratio: 1109.8702371387913
Market cap (USD): 3001869360
Debt to equity: 4.781273581609515
Current ratio: 1.3055272447309332
Quick ratio: 1.3055272447309332
Interest coverage ratio: -39.116680096696214
COGS to revenue (%): 55.52692214406986
R&D to revenue (%): 3.0994366414570154
SG&A to revenue (%): 275.51374771238943
Free cash flow (dilution-adjusted): -1704955
Buyback yield (%): 0
Retained earnings: -8763100
Receivables turnover: 190.7090670170828
Capitalized R&D asset: 26716.690000000002
ROCI (R&D-adjusted, %): -9.614177996755087
Rosenberg metric: -13.104169969874743
FCF margin (%): -234.95620466121318
Revenue growth (%): -11.074292660928217
Rule of 40 score: -246.0304973221414
Financial ratios for KIDZ — quarterly report dated 2025-09-30
Total revenue: 1287638
Gross profit: 899024
Operating income: -631577
Net income: 2520989
Capital expenditures: 0
Operating cash flow: -2549748
Depreciation & amortization: 236835
Net tangible assets: -231056
Owner earnings: 2757824
Return on net tangible assets (%): -1193.5738522263002
Buffett classification: The Gruesome
Stock price: 605
P/E ratio: 122.51771427800757
Shares outstanding: 2042088
Book value: 5400035
P/B ratio: 228.7880060036648
Market cap (USD): 1235463240
Debt to equity: 2.3764371897589553
Current ratio: 1.3712457003734113
Quick ratio: 1.3712457003734113
Effective tax rate (%): 20.837779227817997
Interest coverage ratio: -3.338091890720549
COGS to revenue (%): 30.180376782915697
R&D to revenue (%): 0.4637172870014709
SG&A to revenue (%): 117.14519142802557
Free cash flow (dilution-adjusted): -2691881
Buyback yield (%): 0
Retained earnings: -6242111
Receivables turnover: 55.88949173141195
Capitalized R&D asset: 23121.280000000002
ROCI (R&D-adjusted, %): -3.162288793139682
Rosenberg metric: 25.623849539815925
FCF margin (%): -209.0557283957137
Revenue growth (%): 77.44664079553722
Rule of 40 score: -131.60908760017645
Financial ratios for KIDZ — quarterly report dated 2025-12-31
Total revenue: 537119
Gross profit: 290648
Operating income: -915235
Net income: -5402478
Capital expenditures: 0
Operating cash flow: -652230
Depreciation & amortization: 237676
Net tangible assets: -248988
Owner earnings: -5164802
Buffett classification: The Gruesome
Stock price: 89
Shares outstanding: 2042088
Book value: 3777012
P/B ratio: 48.11894481669637
Market cap (USD): 181745832
Debt to equity: 2.5001879792809767
Current ratio: 1.2139018471336478
Quick ratio: 1.2139018471336478
Interest coverage ratio: -3.8204514906370792
COGS to revenue (%): 45.887596603359775
R&D to revenue (%): 3.6664128433363925
SG&A to revenue (%): 229.9036153999393
Free cash flow (dilution-adjusted): -794363
Buyback yield (%): 0
Retained earnings: -11644589
Receivables turnover: 11.806629591365704
Capitalized R&D asset: 31115.6
ROCI (R&D-adjusted, %): -6.873201109698444
Rosenberg metric: -101.88846089432256
FCF margin (%): -147.89329738847442
Revenue growth (%): -58.28649045772182
Rule of 40 score: -206.17978784619623